Celiac Disease clinical trials at UCLA

1 in progress, 0 open to eligible people

TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Sorry, not currently recruiting here
The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease (CeD) on a gluten-free diet (GFD). Participants will receive TAK-101 and/or placebo through the vein on Day 1 and Day 8. All participants will receive active treatment at Week 24.
Los Angeles, California and other locations

Our lead scientists for Celiac Disease research studies include Guy Weiss.

Last updated: January 29, 2025

TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet